Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

NCT00818623 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix
DRUG: Degarelix

Sponsor

Ferring Pharmaceuticals